The Challenges of Precision Oncology Drug Development and Implementation
The drivers of precision medicine are clear: for patients (and physicians) – more options, durable clinical benefit, reduced exposure to non-effective drugs and potential to leverage current scientific and technological advances; for the pharmaceutical industry – the potential to tackle core challen...
Saved in:
| Published in | Public health genomics Vol. 18; no. 6; pp. 338 - 348 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
S. Karger AG
01.01.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The drivers of precision medicine are clear: for patients (and physicians) – more options, durable clinical benefit, reduced exposure to non-effective drugs and potential to leverage current scientific and technological advances; for the pharmaceutical industry – the potential to tackle core challenges in discovering and developing better and more efficacious medicines, to reduce rates of attrition in drug development and to reduce development costs; for healthcare systems and payers – improved efficiency through the provision of effective care and avoiding ineffective treatments. Oncology has been at the vanguard, the improvements gained in patient survival notable. However, the increasing number of molecular subgroups requires an equally increasing number (and new generation) of highly selective agents targeting inevitably lower incidence molecular segments. Innovative trial designs (umbrella/basket studies) are emerging as a patient-centric approach to drug development, and the rise in public-private partnerships, cross-industry, government and non-profit sector collaborations is enabling implementation of complex clinical trial designs. This poses significant challenges for healthcare systems and regulatory approval. Further substantial evolution of policy and processes, particularly regulatory requirements for approval for new therapeutics, are required. |
|---|---|
| AbstractList | The drivers of precision medicine are clear: for patients (and physicians)--more options, durable clinical benefit, reduced exposure to non-effective drugs and potential to leverage current scientific and technological advances; for the pharmaceutical industry--the potential to tackle core challenges in discovering and developing better and more efficacious medicines, to reduce rates of attrition in drug development and to reduce development costs; for healthcare systems and payers--improved efficiency through the provision of effective care and avoiding ineffective treatments. Oncology has been at the vanguard, the improvements gained in patient survival notable. However, the increasing number of molecular subgroups requires an equally increasing number (and new generation) of highly selective agents targeting inevitably lower incidence molecular segments. Innovative trial designs (umbrella/basket studies) are emerging as a patient-centric approach to drug development, and the rise in public-private partnerships, cross-industry, government and non-profit sector collaborations is enabling implementation of complex clinical trial designs. This poses significant challenges for healthcare systems and regulatory approval. Further substantial evolution of policy and processes, particularly regulatory requirements for approval for new therapeutics, are required. |
| Author | Biankin, Andrew V. Hollingsworth, Simon J. |
| Author_xml | – sequence: 1 givenname: Simon J. surname: Hollingsworth fullname: Hollingsworth, Simon J. – sequence: 2 givenname: Andrew V. surname: Biankin fullname: Biankin, Andrew V. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26555355$$D View this record in MEDLINE/PubMed |
| BookMark | eNpV0E1PwkAQBuBVMSrowbuaHvWAznY7-3E0oEJCggc8N0s7BbTt4m4x8d8LAYmeJpP3mTm8bdaqXU2MXXK45xzNAwAkCUdUB-zCKC0E14DKaDhkZ1zKuKtBiqN_mRKtXZbEiTxl7RDeAWQiQZ6w01giokA8Y4PJnKLe3JYl1TMKkSuiV0_ZIixcHY3rzJVu9h31_WoW9emLSresqG4iW-fRsFqWtNlss8bn7LiwZaCL3eywt-enSW_QHY1fhr3HUTcTRjfdopjKaRFDhkLEXBPgVBiTIaHVYBMrjFKQG10Yiq0qeE4Cc9S5NYBgQYkOu93-XXr3uaLQpNUiZFSWtia3CilXCIngXG7o3ZZm3oXgqUiXflFZ_51ySDfFpvti1_Zm93Y1rSjfy9-m1uBqCz6sn5Hfg_399TZ-D43zf86lVmBi8QOb-IE8 |
| CitedBy_id | crossref_primary_10_1007_s13346_022_01189_4 crossref_primary_10_2217_pme_2016_0061 crossref_primary_10_1016_j_ijrobp_2017_05_044 crossref_primary_10_1038_s41575_019_0109_y crossref_primary_10_1007_s12265_017_9759_8 crossref_primary_10_1038_nrd_2016_175 crossref_primary_10_3389_fmed_2018_00006 crossref_primary_10_1002_jac5_1107 crossref_primary_10_1016_j_ejca_2017_01_012 crossref_primary_10_3390_md16080279 crossref_primary_10_1111_cts_12863 |
| Cites_doi | 10.1158/1078-0432.CCR-12-1627 10.1056/NEJMoa1213261 10.1038/nbt.2696 10.1038/nature09764 10.1038/nbt.2786 10.1158/1535-7163.MCT-12-0290 10.1158/1078-0432.CCR-15-0426 10.1200/JCO.2012.45.3639 10.1158/2159-8274.CD-10-0010 10.1200/JCO.2009.22.3701 10.1002/cncr.28994 10.1038/nrd3979 10.1097/JTO.0000000000000263 10.1200/JCO.2011.39.2779 10.1038/bjc.2014.341 10.1038/nrc3723 10.1038/nrc2870 10.1056/NEJMoa1411817 10.1586/14737159.2015.992417 10.1007/s10549-011-1670-4 10.1056/NEJMoa0909530 10.1038/nrd4309 10.1007/s10549-011-1895-2 10.1148/radiol.12110748 10.1038/nature14169 10.1097/CCO.0000000000000185 |
| ContentType | Journal Article |
| Copyright | 2015 S. Karger AG 2015 S. Karger AG, Basel 2015 S. Karger AG, Basel. |
| Copyright_xml | – notice: 2015 S. Karger AG – notice: 2015 S. Karger AG, Basel – notice: 2015 S. Karger AG, Basel. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1159/000441557 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISBN | 9783318057980 3318057983 |
| EISSN | 1662-8063 |
| EndPage | 348 |
| ExternalDocumentID | 10_1159_000441557 26555355 441557 26687092 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: 17263 – fundername: Wellcome Trust grantid: 103721 |
| GroupedDBID | --- ..I 0R~ 0~5 0~B 123 3O. 3V. 4.4 7X7 88A 88E 88I 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 AAKET AAYIC ABBHK ABJNI ABPAZ ABUWG ABXSQ ABZSI ACGFO ACGFS ACGOD ACHQM ACHQT ACPRK ACPSR ADBBV ADFRT ADULT AENEX AEYAO AFKRA AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CYUIP DU5 DWQXO E0A EBS EJD EMB EMOBN F5P FB. FYUFA GNUQQ GUQSH HCIFZ HMCUK HZ~ IY7 JAAYA JENOY JKPJF JKQEH JLXEF JPL JPM JSODD JST JVCUD KUZGX LK8 M-- M0L M1P M2O M2P M7P O1H O9- PQQKQ PROAC PSQYO RKO SA0 SV3 UJ6 UKHRP ADACV AEJYH AFJJK AILCM ALDHI ALIPV CAG CGR COF CUY CVF ECM EIF GROUPED_DOAJ IAO IHR INH ITC NPM OK1 AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c398t-ffb6bf20c533218e05b399c5e5a80a4a39770d98f9e2a7f1de35d58da9050a073 |
| ISBN | 9783318057973 3318057975 |
| ISSN | 1662-4246 |
| IngestDate | Fri Jun 28 03:32:45 EDT 2024 Thu Sep 26 15:30:56 EDT 2024 Sat Sep 28 08:15:06 EDT 2024 Thu Aug 29 12:04:41 EDT 2024 Fri Feb 02 07:23:21 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Healthcare systems Stratified medicine Precision medicine Oncology Personalised medicine Drug development Targeted drugs |
| Language | English |
| License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. 2015 S. Karger AG, Basel. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c398t-ffb6bf20c533218e05b399c5e5a80a4a39770d98f9e2a7f1de35d58da9050a073 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 26555355 |
| PQID | 1750431167 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | crossref_primary_10_1159_000441557 jstor_primary_26687092 proquest_miscellaneous_1750431167 karger_primary_441557 pubmed_primary_26555355 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-01-01 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – month: 01 year: 2015 text: 2015-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
| PublicationTitle | Public health genomics |
| PublicationTitleAlternate | Public Health Genomics |
| PublicationYear | 2015 |
| Publisher | S. Karger AG |
| Publisher_xml | – name: S. Karger AG |
| References | FoundationOne: What Is FoundationOne? Cambridge, FoundationOne, 2015. Chang DK, Grimmond SM, Evans TJ, Biankin AV: Mining the genomes of exceptional responders. Nat Rev Cancer 2014;14:291-292.2568840210.1038/nrc3723 Yap TA, Sandhu SK, Workman P, de Bono JS: Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514-523.2053513110.1038/nrc2870 Sleijfer S, Bogaerts J, Siu LL: Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013;31:1834-1841.2358955510.1200/JCO.2012.45.3639 Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, Ahn M-J, Kim S-W, Su W-C, Horn L: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-1699.2592354910.1056/NEJMoa1411817 Simon R, Roychowdhury S: Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013;12:358-369.2362950410.1038/nrd3979 EORTC: Colorectal Cancer Screening Platform: SPECTAlung. Brussels, EORTC, 2015. Lindsay CR, Shaw E, Walker I, Johnson PW: Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. Expert Rev Mol Diagn 2015;15:287-289.2554718310.1586/14737159.2015.992417 Pancreatic Cancer Action Network: Know Your Tumor. Manhattan Beach, Pancreatic Cancer Action Network, 2015. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R: Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18:6373-6383.2296601810.1158/1078-0432.CCR-12-1627 US National Cancer Institute: NCI-Match (Molecular Analysis for Therapy Choice). Rockville, US National Cancer Institute, 2015. Foundation Medicine: Learn More about Cancer and Available Treatment Options. Cambridge, Foundation Medicine, 2015. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.2414204910.1038/nbt.2696 US Food and Drug Administration: List of Cleared or Approved Companion Diagnostic Devices (in vitro and Imaging Tools). Silver Spring, US Food and Drug Administration, 2015. Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPACT) trial. Clin Cancer Res 2015;21:2029-2037.2589697310.1158/1078-0432.CCR-15-0426 Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012;132:1049-1062.2219846810.1007/s10549-011-1895-2 Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J: Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51.2440692710.1038/nbt.2786 Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-4034.1959702310.1200/JCO.2009.22.3701 Lung Cancer Master Protocol (Lung-MAP) Clinical Trials: Lung-Map - The Lung Cancer Master Protocol 2013. Association of the British Pharmaceutical Industry: The Stratification of Disease for Personalised Medicines. London, Association of the British Pharmaceutical Industry, 2014. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.2057392610.1056/NEJMoa0909530 Hollebecque A, Massard C, De Baere T, Auger N, Lacroix L, Koubi-Pick V, Vielh P, Lazar V, Bahleda R, Ngo-Camus M: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial-interim results (abstract). J Clin Oncol 2013;31(suppl):2512. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M: Locally advanced breast cancers are more likely to present as interval cancers: results from the I-SPY 1 trial (CALGB 150007/150012, ACRIN 6657, Interspore Trial). Breast Cancer Res Treat 2012;132:871-879.2179636810.1007/s10549-011-1670-4 US Food and Drug Administration: Drug Approvals and Databases. Silver Spring, US Food and Drug Administration, 2015. US Food and Drug Administration: Food and Drug Administration Safety and Innovation Act (FDASIA). Silver Spring, US Food and Drug Administration, 2015. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-3249.2264915210.1200/JCO.2011.39.2779 Lewin J, Siu LL: Cancer genomics: the challenge of drug accessibility. Curr Opin Oncol 2015;27:250-257.2576122310.1097/CCO.0000000000000185 Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S: Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728-1733.11251003 Perthera: Personalized Cancer Therapy. McLean, Perthera, 2015. US Food and Drug Administration: Nucleic Acid Based Tests. Silver Spring, US Food and Drug Administration, 2015. European Medicines Agency: Approvals. London, European Medicines Agency, 2015. Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-501.2571966610.1038/nature14169 Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S: Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY trial. Radiology 2012;263:663-672.2262369210.1148/radiol.12110748 EORTC: Colorectal Cancer Screening Platform: SPECTAcolor. Brussels, EORTC, 2015. English R, Lebovitz Y, Griffin R: Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, National Academies Press, 2010.21210556 Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T: Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345.2512243010.1097/JTO.0000000000000263 Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN: Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 2014;13:419-431.2483329410.1038/nrd4309 Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S: The battle trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.2258631910.1158/2159-8274.CD-10-0010 Dawson S-J, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-1209.2348479710.1056/NEJMoa1213261 Printz C: Failure rate: why many cancer drugs don't receive FDA approval, and what can be done about it. Cancer 2015;121:1529-1530.2594621210.1002/cncr.28994 Academy of Medical Science: Realising the Potential of Stratified Medicine. London, Academy of Medical Science, 2013. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G: Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012;11:2062-2071.2272333610.1158/1535-7163.MCT-12-0290 Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini K, Sotiriou C: The AURORA initiative for metastatic breast cancer. Br J Cancer 2014;111:1881-1887.2522590410.1038/bjc.2014.341 Worldwide Innovative Networking: Worldwide Innovative Networking in Personalised Cancer Medicine. Villejuif, Worldwide Innovative Networking, 2015. Green ED, Guyer MS; National Human Genome Research Institute: Charting a course for genomic medicine from base pairs to bedside. Nature 2011;470:204-213.2130793310.1038/nature09764 Peel N: Stratified medicine and the lung cancer ‘matrix' trial - part of a cancer care revolution. Cancer Research UK Science Blog, 2014. ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref3 doi: 10.1158/1078-0432.CCR-12-1627 – ident: ref18 doi: 10.1056/NEJMoa1213261 – ident: ref17 doi: 10.1038/nbt.2696 – ident: ref1 doi: 10.1038/nature09764 – ident: ref26 doi: 10.1038/nbt.2786 – ident: ref4 doi: 10.1158/1535-7163.MCT-12-0290 – ident: ref13 doi: 10.1158/1078-0432.CCR-15-0426 – ident: ref25 doi: 10.1200/JCO.2012.45.3639 – ident: ref5 doi: 10.1158/2159-8274.CD-10-0010 – ident: ref23 doi: 10.1200/JCO.2009.22.3701 – ident: ref24 doi: 10.1002/cncr.28994 – ident: ref15 doi: 10.1038/nrd3979 – ident: ref19 doi: 10.1097/JTO.0000000000000263 – ident: ref6 doi: 10.1200/JCO.2011.39.2779 – ident: ref14 doi: 10.1038/bjc.2014.341 – ident: ref20 doi: 10.1038/nrc3723 – ident: ref22 doi: 10.1038/nrc2870 – ident: ref12 doi: 10.1056/NEJMoa1411817 – ident: ref10 doi: 10.1586/14737159.2015.992417 – ident: ref9 doi: 10.1007/s10549-011-1670-4 – ident: ref11 doi: 10.1056/NEJMoa0909530 – ident: ref2 doi: 10.1038/nrd4309 – ident: ref7 doi: 10.1007/s10549-011-1895-2 – ident: ref8 doi: 10.1148/radiol.12110748 – ident: ref16 doi: 10.1038/nature14169 – ident: ref21 doi: 10.1097/CCO.0000000000000185 |
| SSID | ssj0064606 |
| Score | 2.1212327 |
| Snippet | The drivers of precision medicine are clear: for patients (and physicians) – more options, durable clinical benefit, reduced exposure to non-effective drugs... The drivers of precision medicine are clear: for patients (and physicians) - more options, durable clinical benefit, reduced exposure to non-effective drugs... The drivers of precision medicine are clear: for patients (and physicians)--more options, durable clinical benefit, reduced exposure to non-effective drugs and... |
| SourceID | proquest crossref pubmed karger jstor |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 338 |
| SubjectTerms | Clinical Trials as Topic - methods Cooperative Behavior Drug Approval Drug Discovery - economics Drug Discovery - trends Drug Industry - economics Further Section Humans Medical Oncology - methods Molecular Targeted Therapy Patient Selection Precision Medicine - methods Precision Medicine - trends Public-Private Sector Partnerships |
| Title | The Challenges of Precision Oncology Drug Development and Implementation |
| URI | https://www.jstor.org/stable/26687092 https://karger.com/doi/10.1159/000441557 https://www.ncbi.nlm.nih.gov/pubmed/26555355 https://search.proquest.com/docview/1750431167 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6xTSBeEBsbFNhkJt6qlMSJE_sRuk3VpP3QfqC-RY7jgDSRotI-wF_POXacdAVp8BJVaR2lvi_n75zv7gDeqyzhKmGFycaRGKAoGQhZioDFFQ1VRFPKTXLy2Xk6uU1Op2za9e9ssksWxUj9-mNeyf9YFc-hXU2W7D9Y1l8UT-BntC8e0cJ4fLCNx203FCtnm7ueOcOLWtnySkfz5Ze-NsgqgL-1unFvGMdQL3t1r7-aBssmbdkT74mt4d0pC6_R1vXwdNRttsv6rq1LYLSSw8-j_s5CxHo7C9YZpiajirotQt2d46FzSmse9J47jG3lFreyxram5rrTZsKqHE1sZ8tVrxbGvrdgeRlhE8AwkfuhG7BFM8EwCN_6dHx-edWuyWmSNl1W_T9yNaZw8Ac_eIWZWHEq0pI7I8if_z3-aHjIzXN45gII8tGiYRse6XoHHtuWoj934MmZE0u8gAnCg3TwILOKeHiQFh7EwIP04EEQHmQVHrtwe3J8M54ErnFGoGLBF0FVFWlhnjXk8kjhdMgK5KGKaSZ5KBNpSH9YCl4JTWVWRaWOWcl4KUXIQolOfw8261mtXwHhTFdI0TFs0GVCM4rPccGlKMI4FqnkagCH7aTl3219lHzNLAPYa6bT_wJZIa4Tgg5g186v_6Yd8K6d7hzdnXmHJWs9W_7II9OOIDYvDwfw0tqhd1XGGPLn1w-5pzfwtMP8W9hczJd6H_nlojiAjWya4ZGPowMHpN-Y6nfG |
| link.rule.ids | 315,786,790,27957,27958,31755,33302,33780 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Challenges+of+Precision+Oncology+Drug+Development+and+Implementation&rft.jtitle=Public+health+genomics&rft.au=Hollingsworth%2C+Simon+J.&rft.au=Biankin%2C+Andrew+V.&rft.date=2015-01-01&rft.issn=1662-4246&rft.eissn=1662-8063&rft.volume=18&rft.issue=6&rft.spage=338&rft.epage=348&rft_id=info:doi/10.1159%2F000441557&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000441557 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1662-4246&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1662-4246&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1662-4246&client=summon |